300436 广生堂
已收盘 03-13 15:00:00
资讯
新帖
简况
3月13日广生堂涨8.72%，广发睿恒进取一年持有期混合A基金重仓该股
证券之星 · 03-13 16:26
3月13日广生堂涨8.72%，广发睿恒进取一年持有期混合A基金重仓该股
2月9日广生堂跌5.28%，广发睿恒进取一年持有期混合A基金重仓该股
证券之星 · 02-09
2月9日广生堂跌5.28%，广发睿恒进取一年持有期混合A基金重仓该股
2月5日广生堂涨12.94%，广发睿恒进取一年持有期混合A基金重仓该股
证券之星 · 02-05
2月5日广生堂涨12.94%，广发睿恒进取一年持有期混合A基金重仓该股
广生堂(300436.SZ)：奈瑞可韦GST-HG141完成III期临床试验受试者入组
智通财经 · 02-04
广生堂(300436.SZ)：奈瑞可韦GST-HG141完成III期临床试验受试者入组
2月3日广生堂涨5.78%，广发睿恒进取一年持有期混合A基金重仓该股
证券之星 · 02-03
2月3日广生堂涨5.78%，广发睿恒进取一年持有期混合A基金重仓该股
广生堂（300436）披露2025年度业绩预告，1月30日股价下跌7.26%
证券之星 · 01-30
广生堂（300436）披露2025年度业绩预告，1月30日股价下跌7.26%
广生堂(300436.SZ)发预亏，预计2025年度归母净亏损1.7亿元至2.4亿元
智通财经 · 01-30
广生堂(300436.SZ)发预亏，预计2025年度归母净亏损1.7亿元至2.4亿元
1月30日广生堂跌7.26%，广发睿恒进取一年持有期混合A基金重仓该股
证券之星 · 01-30
1月30日广生堂跌7.26%，广发睿恒进取一年持有期混合A基金重仓该股
广生堂：国家推进“筛-诊-治”一体化体系建设
证券之星 · 01-30
广生堂：国家推进“筛-诊-治”一体化体系建设
广生堂：同时拥有核心蛋白抑制剂GST-HG141和口服表面抗原抑制剂GST-HG131
证券之星 · 01-29
广生堂：同时拥有核心蛋白抑制剂GST-HG141和口服表面抗原抑制剂GST-HG131
广生堂：管理层聚焦高质量推进创新药临床研究
证券之星 · 01-29
广生堂：管理层聚焦高质量推进创新药临床研究
1月28日广生堂涨14.00%，广发睿恒进取一年持有期混合A基金重仓该股
证券之星 · 01-28
1月28日广生堂涨14.00%，广发睿恒进取一年持有期混合A基金重仓该股
1月27日广生堂跌8.71%，广发睿恒进取一年持有期混合A基金重仓该股
证券之星 · 01-27
1月27日广生堂跌8.71%，广发睿恒进取一年持有期混合A基金重仓该股
异动快报：广生堂（300436）1月23日10点21分触及涨停板
证券之星 · 01-23
异动快报：广生堂（300436）1月23日10点21分触及涨停板
广生堂（300436）披露2025年度向特定对象发行A股股票募集说明书（修订稿），1月12日股价下跌1.08%
证券之星 · 01-12
广生堂（300436）披露2025年度向特定对象发行A股股票募集说明书（修订稿），1月12日股价下跌1.08%
股市必读：广生堂（300436）1月8日董秘有最新回复
证券之星 · 01-09
股市必读：广生堂（300436）1月8日董秘有最新回复
广生堂：GST-HG141 III期临床进展符合预期
证券之星 · 01-08
广生堂：GST-HG141 III期临床进展符合预期
广生堂最新公告：创新药子公司参与新发突发与重大传染病防控国家科技重大专项
证券之星 · 01-05
广生堂最新公告：创新药子公司参与新发突发与重大传染病防控国家科技重大专项
广生堂：GST-HG141 III期临床暂无中期揭盲计划
证券之星 · 2025-12-03
广生堂：GST-HG141 III期临床暂无中期揭盲计划
广生堂：创新药GST-HG141临床三期试验正按计划推进
证券之星 · 2025-11-20
广生堂：创新药GST-HG141临床三期试验正按计划推进
暂无数据
公司概况
公司名称：
福建广生堂药业股份有限公司
所属行业：
医药制造业
上市日期：
2015-04-22
主营业务：
福建广生堂药业股份有限公司的主营业务是核苷类抗乙肝病毒药物的研发、生产与销售。公司的主要产品是丙酚替诺福韦、替诺福韦、恩替卡韦、拉米夫定、阿德福韦酯五大核苷（酸）类抗乙肝病毒用药。公司获第二十三届中国国际高新技术成果交易会“优秀产品奖”。
发行价格：
21.47
{"stockData":{"symbol":"300436","market":"SZ","secType":"STK","nameCN":"广生堂","latestPrice":111.17,"timestamp":1773385422000,"preClose":102.25,"halted":0,"volume":14234208,"delay":0,"changeRate":0.0872,"floatShares":137000000,"shares":159000000,"eps":-1.2385,"marketStatus":"已收盘","change":8.92,"latestTime":"03-13 15:00:00","open":102.25,"high":118.6,"low":100.51,"amount":1582000000,"amplitude":0.1769,"askPrice":111.18,"askSize":5,"bidPrice":111.17,"bidSize":96,"shortable":0,"etf":0,"ttmEps":-1.2385,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1773624600000},"marketStatusCode":5,"adr":0,"adjPreClose":102.25,"symbolType":"stock","openAndCloseTimeList":[[1773365400000,1773372600000],[1773378000000,1773385200000]],"highLimit":112.48,"lowLimit":92.03,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":159267000,"isCdr":false,"pbRate":42.52,"roa":"--","roe":"--","epsLYR":-0.9814,"committee":0.197861,"marketValue":17706000000,"turnoverRate":0.1041,"status":0,"floatMarketCap":15199000000},"requestUrl":"/m/hq/s/300436/tweets","defaultTab":"tweets","newsList":[{"id":"2619162905","title":"3月13日广生堂涨8.72%，广发睿恒进取一年持有期混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2619162905","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619162905?lang=zh_cn&edition=full","pubTime":"2026-03-13 16:26","pubTimestamp":1773390398,"startTime":"0","endTime":"0","summary":"证券之星消息，3月13日广生堂涨8.72%，收盘报111.17元，换手率10.41%，成交量14.23万手，成交额15.82亿元。重仓广生堂的公募基金请见下表：根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为广发基金的广发睿恒进取一年持有期混合A。广发睿恒进取一年持有期混合A目前规模为1.17亿元，最新净值1.1708，较上一交易日下跌1.16%，近一年上涨32.34%。该公募基金现任基金经理为林英睿 郭绍军。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031300027327.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300436"],"gpt_icon":0},{"id":"2610638887","title":"2月9日广生堂跌5.28%，广发睿恒进取一年持有期混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2610638887","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610638887?lang=zh_cn&edition=full","pubTime":"2026-02-09 16:39","pubTimestamp":1770626344,"startTime":"0","endTime":"0","summary":"证券之星消息，2月9日广生堂跌5.28%，收盘报122.55元，换手率15.19%，成交量20.76万手，成交额26.21亿元。重仓广生堂的公募基金请见下表：根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为广发基金的广发睿恒进取一年持有期混合A。广发睿恒进取一年持有期混合A目前规模为1.17亿元，最新净值1.1473，较上一交易日上涨0.05%，近一年上涨36.1%。该公募基金现任基金经理为林英睿 郭绍军。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020900020299.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300436","BK0239"],"gpt_icon":0},{"id":"2609219322","title":"2月5日广生堂涨12.94%，广发睿恒进取一年持有期混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2609219322","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609219322?lang=zh_cn&edition=full","pubTime":"2026-02-05 16:40","pubTimestamp":1770280855,"startTime":"0","endTime":"0","summary":"证券之星消息，2月5日广生堂涨12.94%创60日新高，收盘报131.02元，换手率14.29%，成交量19.54万手，成交额24.32亿元。重仓广生堂的公募基金请见下表：根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为广发基金的广发睿恒进取一年持有期混合A。广发睿恒进取一年持有期混合A目前规模为1.17亿元，最新净值1.1542，较上一交易日下跌0.16%，近一年上涨35.39%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020500026267.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300436","BK0239"],"gpt_icon":0},{"id":"2608359175","title":"广生堂(300436.SZ)：奈瑞可韦GST-HG141完成III期临床试验受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2608359175","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608359175?lang=zh_cn&edition=full","pubTime":"2026-02-04 16:43","pubTimestamp":1770194609,"startTime":"0","endTime":"0","summary":"智通财经APP讯，广生堂(300436.SZ)公告，公司创新药控股子公司福建广生中霖生物科技有限公司的在研乙肝治疗一类创新药奈瑞可韦GST-HG141的III期临床试验，已于近日完成全部受试者入组，合计入组578例。本次GST-HG141完成III期临床试验全部受试者入组后，尚需按照已制定临床方案和要求继续推进临床试验，并经国家药品审评部门注册审批通过后方可上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401558.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK4134","GST","III","300436"],"gpt_icon":0},{"id":"2608826318","title":"2月3日广生堂涨5.78%，广发睿恒进取一年持有期混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2608826318","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608826318?lang=zh_cn&edition=full","pubTime":"2026-02-03 16:48","pubTimestamp":1770108497,"startTime":"0","endTime":"0","summary":"证券之星消息，2月3日广生堂涨5.78%，收盘报107.92元，换手率9.93%，成交量13.57万手，成交额14.36亿元。重仓广生堂的公募基金请见下表：根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为广发基金的广发睿恒进取一年持有期混合A。广发睿恒进取一年持有期混合A目前规模为1.17亿元，最新净值1.1375，较上一交易日下跌1.84%，近一年上涨33.43%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020300028296.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300436"],"gpt_icon":0},{"id":"2607049971","title":"广生堂（300436）披露2025年度业绩预告，1月30日股价下跌7.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607049971","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607049971?lang=zh_cn&edition=full","pubTime":"2026-01-30 22:13","pubTimestamp":1769782434,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，广生堂报收于99.65元，较前一交易日下跌7.26%，最新总市值为158.71亿元。该股当日开盘104.0元，最高105.5元，最低97.89元，成交额达11.85亿元，换手率为8.62%。近日，广生堂发布《2025年度业绩预告》。公告显示，公司预计2025年度归属于上市公司股东的净利润亏损17,000万元至24,000万元，上年同期为亏损15,630.44万元；扣除非经常性损益后的净利润预计亏损17,750万元至24,750万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000046994.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300436"],"gpt_icon":0},{"id":"2607853015","title":"广生堂(300436.SZ)发预亏，预计2025年度归母净亏损1.7亿元至2.4亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607853015","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607853015?lang=zh_cn&edition=full","pubTime":"2026-01-30 17:37","pubTimestamp":1769765862,"startTime":"0","endTime":"0","summary":"智通财经APP讯，广生堂(300436.SZ)披露2025年度业绩预告，公司预计归属于上市公司股东的净亏损1.7亿元至2.4亿元;扣除非经常性损益后的净亏损1.78亿元至2.48亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399855.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"广生堂(300436.SZ)发预亏，预计2025年度归母净亏损1.7亿元至2.4亿元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300436"],"gpt_icon":0},{"id":"2607090909","title":"1月30日广生堂跌7.26%，广发睿恒进取一年持有期混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2607090909","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607090909?lang=zh_cn&edition=full","pubTime":"2026-01-30 16:42","pubTimestamp":1769762543,"startTime":"0","endTime":"0","summary":"证券之星消息，1月30日广生堂跌7.26%，收盘报99.65元，换手率8.62%，成交量11.78万手，成交额11.85亿元。重仓广生堂的公募基金请见下表：根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为广发基金的广发睿恒进取一年持有期混合A。广发睿恒进取一年持有期混合A目前规模为1.17亿元，最新净值1.1547，较上一交易日下跌0.77%，近一年上涨35.45%。该公募基金现任基金经理为林英睿 郭绍军。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000028035.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300436"],"gpt_icon":0},{"id":"2607640220","title":"广生堂：国家推进“筛-诊-治”一体化体系建设","url":"https://stock-news.laohu8.com/highlight/detail?id=2607640220","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607640220?lang=zh_cn&edition=full","pubTime":"2026-01-30 11:30","pubTimestamp":1769743824,"startTime":"0","endTime":"0","summary":"证券之星消息，广生堂01月30日在投资者关系平台上答复投资者关心的问题。国家推进“筛-诊-治”一体化体系建设，有望显著提升慢性乙肝患者的规范管理覆盖率和治疗可及性，对乙肝药物市场具有积极意义。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000016375.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300436"],"gpt_icon":0},{"id":"2607087850","title":"广生堂：同时拥有核心蛋白抑制剂GST-HG141和口服表面抗原抑制剂GST-HG131","url":"https://stock-news.laohu8.com/highlight/detail?id=2607087850","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607087850?lang=zh_cn&edition=full","pubTime":"2026-01-29 20:52","pubTimestamp":1769691125,"startTime":"0","endTime":"0","summary":"证券之星消息，广生堂01月28日在投资者关系平台上答复投资者关心的问题。根据已获取的公开信息，在乙肝创新药领域存在处于不同开发阶段不同机制的多款候选药物，公司作为同时拥有核心蛋白抑制剂GST-HG141和口服表面抗原抑制剂GST-HG131的企业在同机制药物中具有领先性和差异化组合优势。公司将持续积极推动相关药物的研发和上市，以获取更多确证性的临床数据来验证产品的潜力与临床价值，争取早日上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900040917.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300436"],"gpt_icon":0},{"id":"2607272710","title":"广生堂：管理层聚焦高质量推进创新药临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2607272710","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607272710?lang=zh_cn&edition=full","pubTime":"2026-01-29 09:06","pubTimestamp":1769648767,"startTime":"0","endTime":"0","summary":"证券之星消息，广生堂01月28日在投资者关系平台上答复投资者关心的问题。市值受多重因素影响，包括但不限于研发进展、监管审批结果、企业经营业绩、资本市环境、行业政策及宏观经济等，且创新药研发周期长、投入大、风险高，敬请投资者注意投资风险。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900007004.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","BK1574","159992","BK0239","300436","BK1161"],"gpt_icon":0},{"id":"2606879618","title":"1月28日广生堂涨14.00%，广发睿恒进取一年持有期混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2606879618","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606879618?lang=zh_cn&edition=full","pubTime":"2026-01-28 16:42","pubTimestamp":1769589724,"startTime":"0","endTime":"0","summary":"证券之星消息，1月28日广生堂涨14.00%，收盘报105.01元，换手率15.78%，成交量21.58万手，成交额22.03亿元。重仓广生堂的公募基金请见下表：根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为广发基金的广发睿恒进取一年持有期混合A。广发睿恒进取一年持有期混合A目前规模为1.17亿元，最新净值1.1746，较上一交易日上涨0.18%，近一年上涨37.78%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800027710.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300436","BK0239"],"gpt_icon":0},{"id":"2606204355","title":"1月27日广生堂跌8.71%，广发睿恒进取一年持有期混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2606204355","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606204355?lang=zh_cn&edition=full","pubTime":"2026-01-27 16:39","pubTimestamp":1769503167,"startTime":"0","endTime":"0","summary":"证券之星消息，1月27日广生堂跌8.71%，收盘报92.11元，换手率11.13%，成交量15.22万手，成交额14.4亿元。重仓广生堂的公募基金请见下表：根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为广发基金的广发睿恒进取一年持有期混合A。广发睿恒进取一年持有期混合A目前规模为1.17亿元，最新净值1.1725，较上一交易日下跌0.64%，近一年上涨35.93%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012700027216.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300436","BK0239"],"gpt_icon":0},{"id":"2605540447","title":"异动快报：广生堂（300436）1月23日10点21分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2605540447","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605540447?lang=zh_cn&edition=full","pubTime":"2026-01-23 10:25","pubTimestamp":1769135124,"startTime":"0","endTime":"0","summary":"证券之星1月23日盘中消息，10点21分广生堂触及涨停板。其所属行业化学制药目前上涨。该股为肝炎概念，创新药，医药概念热股，当日肝炎概念概念上涨2.16%，创新药概念上涨1.55%，医药概念上涨1.3%。1月22日的资金流向数据方面，主力资金净流入80.55万元，占总成交额0.36%，游资资金净流出702.57万元，占总成交额3.15%，散户资金净流入622.02万元，占总成交额2.79%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012300011443.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300436","BK0239"],"gpt_icon":0},{"id":"2602316545","title":"广生堂（300436）披露2025年度向特定对象发行A股股票募集说明书（修订稿），1月12日股价下跌1.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602316545","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602316545?lang=zh_cn&edition=full","pubTime":"2026-01-12 22:08","pubTimestamp":1768226902,"startTime":"0","endTime":"0","summary":"截至2026年1月12日收盘，广生堂报收于93.38元，较前一交易日下跌1.08%，最新总市值为148.72亿元。近日，广生堂发布《2025年度向特定对象发行A股股票募集说明书（修订稿）》。公告显示，福建广生堂药业股份有限公司拟向特定对象发行A股股票，募集资金总额不超过97,686.65万元，用于创新药研发项目、中药传统名方产业化项目及补充流动资金。发行对象为不超过35名特定投资者，发行价格不低于定价基准日前二十个交易日股票交易均价的80%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200036961.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["399300","BK0239","300436","159982"],"gpt_icon":0},{"id":"2602139181","title":"股市必读：广生堂（300436）1月8日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2602139181","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602139181?lang=zh_cn&edition=full","pubTime":"2026-01-09 01:07","pubTimestamp":1767892031,"startTime":"0","endTime":"0","summary":"截至2026年1月8日收盘，广生堂报收于91.07元，下跌1.19%，换手率3.93%，成交量5.37万手，成交额4.91亿元。董秘最新回复投资者： 董秘你好！同行进展反映全球对乙肝治愈的重视，有助于推动整体研发进程。我司将加快推进GST-HG141临床开发，力争为更多患者提供创新治疗方案。后续进展公司将依法依规及时披露，敬请持续关注。当日关注点来自交易信息汇总：1月8日主力资金净流出2176.52万元，散户资金净流入3362.58万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900000801.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300436","BK0239"],"gpt_icon":0},{"id":"2601936117","title":"广生堂：GST-HG141 III期临床进展符合预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2601936117","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601936117?lang=zh_cn&edition=full","pubTime":"2026-01-08 20:49","pubTimestamp":1767876554,"startTime":"0","endTime":"0","summary":"证券之星消息，广生堂01月08日在投资者关系平台上答复投资者关心的问题。投资者提问：您好董秘，请问公司141产品三期临床进展怎么样了？我司GST-HG141的III期临床试验正在顺利推进，目前入组人数已过半，整体进展符合预期，且日前GST-HG141相关研究已被纳入新发突发与重大传染病防控国家科技重大专项，有望依托国家重大专项的资源与政策支持，加快研发进展，力争早日获批上市，惠及广大患者。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010800036846.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300436","BK0239"],"gpt_icon":0},{"id":"2601885487","title":"广生堂最新公告：创新药子公司参与新发突发与重大传染病防控国家科技重大专项","url":"https://stock-news.laohu8.com/highlight/detail?id=2601885487","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601885487?lang=zh_cn&edition=full","pubTime":"2026-01-05 19:41","pubTimestamp":1767613278,"startTime":"0","endTime":"0","summary":"广生堂(300436.SZ)公告称，公司创新药控股子公司广生中霖参与的新发突发与重大传染病防控国家科技重大专项“慢性乙型肝炎临床治愈联合治疗新方案研究”项目已获立项完成通知。广生中霖负责课题一和课题三的研究工作，将使用在研乙肝创新药GST-HG131、GST-HG141及联合用药作为项目课题研究用药。该项目旨在探索提高乙肝临床治愈率的联合新方案，对公司在乙肝治疗领域的技术创新能力和研发实力是肯定，体现了公司在相关领域的核心竞争力。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500034198.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300436","BK1161","06978","BK1574","159992","BK0239"],"gpt_icon":0},{"id":"2588750046","title":"广生堂：GST-HG141 III期临床暂无中期揭盲计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2588750046","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588750046?lang=zh_cn&edition=full","pubTime":"2025-12-03 20:51","pubTimestamp":1764766288,"startTime":"0","endTime":"0","summary":"证券之星消息，广生堂(300436)12月02日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好: 请问广生堂141三期临床会不会出中期数据？如果会的话大概在什么时候出？广生堂回复：尊敬的投资者，您好！GST-HG141的III期临床试验是一项48周治疗的随机双盲研究，是公司创新药研发管线的重点项目，正按计划全力推进。为确保数据的完整性，公司目前暂未安排该试验中期揭盲分析计划。公司将持续高效推进试验进程并及时披露创新药重大进展，感谢您的关注和支持！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300037194.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300436","BK0239"],"gpt_icon":0},{"id":"2584131758","title":"广生堂：创新药GST-HG141临床三期试验正按计划推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2584131758","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584131758?lang=zh_cn&edition=full","pubTime":"2025-11-20 20:51","pubTimestamp":1763643090,"startTime":"0","endTime":"0","summary":"证券之星消息，广生堂11月19日在投资者关系平台上答复投资者关心的问题。公司是否应该适时公布入组人数进展，让广大投资者安心广生堂回复：投资者，您好。今年7月首例患者入组的是公司乙肝治疗创新药GST-HG141的临床三期试验，目前正按计划顺利推进。截至目前具体的患者入组人数涉及临床试验的保密性，且为避免对临床进展不必要的干扰，暂不便对外披露，请您理解。公司将在创新药研究重大进展时及时履行信息披露，感谢您的关注！","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112000035562.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1574","300436","BK0239","159992","06978"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1773419044713,"stockEarnings":[{"period":"1week","weight":0.0389},{"period":"1month","weight":-0.1558},{"period":"3month","weight":0.2287},{"period":"6month","weight":-0.0736},{"period":"1year","weight":2.0292},{"period":"ytd","weight":0.247}],"compareEarnings":[{"period":"1week","weight":-0.007},{"period":"1month","weight":-0.0088},{"period":"3month","weight":0.053},{"period":"6month","weight":0.0581},{"period":"1year","weight":0.2193},{"period":"ytd","weight":0.0319}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"福建广生堂药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"45797人(较上一季度增加125.95%)","perCapita":"2985股","listingDate":"2015-04-22","address":"福建省宁德市柘荣县富源工业园区1-7幢","registeredCapital":"15926万元","survey":" 福建广生堂药业股份有限公司的主营业务是核苷类抗乙肝病毒药物的研发、生产与销售。公司的主要产品是丙酚替诺福韦、替诺福韦、恩替卡韦、拉米夫定、阿德福韦酯五大核苷（酸）类抗乙肝病毒用药。公司获第二十三届中国国际高新技术成果交易会“优秀产品奖”。","listedPrice":21.47},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"广生堂(300436)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供广生堂(300436)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"广生堂,300436,广生堂股票,广生堂股票老虎,广生堂股票老虎国际,广生堂行情,广生堂股票行情,广生堂股价,广生堂股市,广生堂股票价格,广生堂股票交易,广生堂股票购买,广生堂股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"广生堂(300436)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供广生堂(300436)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}